An interventional study of AI-CIMCare Chatbot and Empowerment Application for CAM Health Education in Diabetes, sponsored by Chang Gung University of Science and Technology. Active, not recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Chang Gung University of Science and Technology · Not applicable, Interventional, and Health services research
Performance analysis of the AI-CIMCare Chatbot is an essential way to ensure its impact on the promotion of patient-based outcomes in patients with diabetes.
A randomized controlled trial is to determine a cause-effect relation which exists between the intervention and the outcomes by avoiding contamination across individuals (Polit \& Beck, 2022). The chatbot for patients with diabetes in the management of CIM use alongside conventional diabetes treatment will be trained well at the end of the phase II study. The objectives of this phase are to (1) implement the chatbot to empower patients with diabetes in their management of diabetes alongside CAM use, (2) examine the impact of the chatbot on CIM health literacy, patient empowerment, user engagement, clinical outcomes and facilitate communication with HCPs in patients with diabetes, and (3) collect feedback from patients on how to improve the chatbot for dissemination and implementation.
8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
This study's planned enrollment of 113 is above the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Chang Gung University of Science and Technology is the lead sponsor of 43 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AI-CIMCare Chatbot plus Empowerment Application for CAM Health Education
Behavioral: AI-CIMCare Chatbot · Behavioral: Empowerment Application for CAM Health Education
Empowerment Application for CAM Health Education
Behavioral: Empowerment Application for CAM Health Education
The intervention will be carried out over a 12-week period, which contains four sections: (1) knowledge on benefit-risk assessment of CIM use; (2) short videos regarding information and skills necessary to seek, assess; (3) evaluate how to be critical for wise and safe use of CIM; and (4) linkage of government websites and the decision-making algorithm on the Benefit-Risk Assessment of CIM Use for People with Diabetes.
Also known as: Empowerment Application for CAM
Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
Understanding the benefits and risks of complementary therapies (CTs) use scale
The 15-item scale assesses patients' awareness of CIM use in diabetes. The maximum score is 4 points, and the minimum score is 1 point for each item. Scores range from 15-60, with higher scores indicating greater understanding.
Time frame: Pre-test (baseline),4,8,12 weeks after intervention
Patient empowerment
The 10-item Diabetes Empowerment Scale assesses patients' perceived control and readiness for diabetes self-management. Maximum score is 4 points, minimum score is 1 point for each item. Scores range from 10-50, with higher scores indicating greater empowerment. The scale showed acceptable reliability (α = .77) and established construct and criterion validity.
Time frame: Pre-test (baseline),4,8,12 weeks after intervention
System Usability Scale (SUS)
The 10-item questionnaire measures how easy a product, system, or website is to use. The maximum score is 5 points, and the minimum is 1 point per item. Scores range from 10-50, with higher scores indicating greater usability.
Time frame: Pre-test (baseline) and 12 weeks after intervention
Quality of life
The 15-item quality-of-life measure for Chinese patients with diabetes will be used to assess their life satisfaction. The maximum score is 5 points, and the minimum score is 1 point. Scores range from 15-75, with higher scores indicating greater life satisfaction.
Time frame: Pre-test (baseline) and 12 weeks after intervention
Patient-HCP Communication
The 10-item Details of CIM Use Survey, designed by Chang et al. (2011) with good content validity, assesses patterns of CIM use, experiences of CIM use, and disclosure of CIM use to HCPs.
Time frame: Pre-test (baseline) and 12 weeks after intervention
Glycated Hemoglobin blood test
It measures the average blood sugar levels over the past two to three months. Unit of Measurement: Percentage (%).
Time frame: Pre-test (baseline) and 12 weeks after intervention
Fasting Plasma Glucose blood test
A patient has fasted (no food or drink except water) for at least 8 hours to measure baseline blood sugar levels. Unit of Measurement: mg/dL (milligrams per deciliter)
Time frame: Pre-test (baseline) and 12 weeks after intervention
Cholesterol blood test
It measures the weight of cholesterol in milligrams per deciliter of blood. Unit of Measurement: Unit of Measurement: mg/dL (milligrams per deciliter)
Time frame: Pre-test (baseline) and 12 weeks after intervention
Triglycerides blood test
It measures serum or plasma triglyceride concentration. Unit of Measurement: mg/dL (milligrams per deciliter)
Time frame: Pre-test (baseline) and 12 weeks after intervention
Aspartate aminotransferase (AST) blood test
It helps determine liver function. Unit of Measurement: units per liter (U/L).
Time frame: Pre-test (baseline) and 12 weeks after intervention
Alanine aminotransferase (ALT) blood test
It helps determine liver function. Unit of Measurement: units per liter (U/L).
Time frame: Pre-test (baseline) and 12 weeks after intervention
Blood urea nitrogen (BUN) blood test
It measures kidney filtration of protein waste. Unit of Measurement: milligrams per deciliter (mg/dL)
Time frame: Pre-test (baseline) and 12 weeks after intervention
Creatinine (Cr) blood test
It measures how well the kidneys. Unit of Measurement: mg/dL (milligrams per deciliter)
Time frame: Pre-test (baseline) and 12 weeks after intervention
estimated GFR (eGFR) test
It measures the volume of blood (in milliliters) filtered by the kidneys each minute. Unit of Measurement: milliliters per minute adjusted for body surface area mL/min/1.73m²
Time frame: Pre-test (baseline) and 12 weeks after intervention
Albumin-to-Creatinine Ratio (ACR) Urinalysis
It is reported in milligrams per millimole (mg/mmol) or milligrams per gram (mg/g)
Time frame: Pre-test (baseline) and 12 weeks after intervention
Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 11 months after the start.
Of 1,583 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 1,743 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chang Gung University of Science and Technology